IFIT3 and breast carcinoma: Doxorubicin-resistant cisplatin-sensitive BrCCh1 primary breast cancer cells exhibit low baseline IFIT3 mRNA with a prominent response to stimulation with a small nucleolar RNA analogue or IFNα, suggesting that IFIT3 can function as a predictive marker for immunostimulant treatments in breast cancer [95].